Boston Scientific announces results for fourth quarter and full year 2025
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Boston Scientific (BSX) PT Lowered to $105 at Piper Sandler, 'Buy The Dip'
February 4, 2026 9:46 AM EST(Updated - February 4, 2026 9:52 AM EST)
Piper Sandler analyst Matt O\'Brien lowered the price target on Boston Scientific (NYSE: BSX) to $105.00 (from $120.00) while maintaining a Overweight rating.
"Q4 Beat But Key Drivers Deceleration to Weight on Stock; Buy The Dip"... MoreBoston Scientific (BSX) Tops Q4 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance
February 4, 2026 6:31 AM ESTBoston Scientific (NYSE: BSX) reported Q4 EPS of $0.80, $0.02 better than the analyst estimate of $0.78. Revenue for the quarter came in at $5.29 billion versus the consensus estimate of $5.28 billion.
GUIDANCE:
Boston Scientific sees FY2026 EPS of $3.43-$3.49, versus the consensus of... More
